ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
23 avr. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
ITM Obtains Manufacturing License in the U.S.
01 févr. 2024 07h00 HE
|
ITM Isotope Technologies Munich SE
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and...
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
30 janv. 2024 07h00 HE
|
ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
16 janv. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
04 janv. 2024 07h54 HE
|
ITM Isotope Technologies Munich SE
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP manufacturing capabilities to...
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
14 déc. 2023 09h28 HE
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
14 déc. 2023 09h26 HE
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens...
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
24 oct. 2023 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, October 24, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today reported on its participation at the 3rd International...
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
18 oct. 2023 08h00 HE
|
ITM Isotope Technologies Munich SE
New company will advance Actinium-225 technologies, quickly secure supply, and construct a new production facility in Canada to produce industrial-scale quantities of rare medical isotope ...